.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Gastric cancer remains a global health challenge, especially in advanced stages where the prognosis is often guarded. However, the discovery of Claudin-18.2 (CLDN18.2) as a specific therapeutic target is shifting treatment paradigms. Researchers are increasingly prioritizing Claudin 18.2 gastric cancer studies to address the significant unmet medical needs in this patient population.
A recent systematic analysis of the global landscape identified 143 clinical trials targeting this biomarker. While research has surged since 2021, nearly 70% of these trials currently remain in early-phase exploration. Notably, the successful progression of drugs into phase II and III trials indicates a maturing pipeline. For instance, zolbetuximab has recently entered phase IV trials, marking its transition into post-market surveillance and real-world clinical application.
The variety of drug types under investigation reflects continuous innovation. Monoclonal antibodies constitute over 32% of trials, while antibody-drug conjugates (ADCs) represent approximately 26%. Furthermore, CAR-T therapies have gained significant traction, representing over 23% of the current clinical landscape. Other modalities, such as bispecific antibodies and CAR-NK cells, are also entering the arena. Consequently, these diverse strategies offer multiple avenues for personalized treatment.
Geographically, trial activity centers on East Asia, North America, and Europe. China currently leads in both independent and collaborative research efforts. Meanwhile, the United States maintains the broadest international partnership network. This global synergy is essential for accelerating the development of novel therapies. Therefore, patients worldwide may soon benefit from more refined and effective treatment options.
Claudin 18.2 is a protein that maintains gastric mucosal tight junctions. In malignant cells, it becomes exposed, allowing targeted drugs to bind specifically to tumor tissue while sparing most healthy organs. This selectivity reduces off-target toxicity and improves the therapeutic index.
Zolbetuximab is the most advanced monoclonal antibody, showing improved survival when combined with chemotherapy in high-expression patients. Additionally, antibody-drug conjugates (ADCs) and CAR-T therapies are showing promising results in early and mid-phase clinical trials for metastatic disease.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A comprehensive analysis of 143 clinical trials for CLDN18.2-positive gastric cancer, highlighting zolbetuximab, ADCs, and emerging CAR-T therapies....
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
